Literature DB >> 34011825

Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia.

Hayato Tada1, Hirofumi Okada1, Atsushi Nohara2, Masakazu Yamagishi3, Masayuki Takamura1, Masa-Aki Kawashiri1.   

Abstract

BACKGROUND: Recent studies suggest that cumulative exposure to low-density lipoprotein-cholesterol (LDL-C) leads to the development of atherosclerotic cardiovascular disease (ASCVD). However, few studies have investigated whether this link extends to individuals with familial hypercholesterolemia (FH), a relevant patient population.Methods and 
Results: We retrospectively investigated the health records of 1,050 patients with clinical FH diagnosis between April 1990 and March 2019. We used Cox proportional hazards models adjusted for established ASCVD risk factors to assess the association between cholesterol-year-score and major adverse cardiovascular events (MACEs), including death from any cause or hospitalization due to ASCVD events. Cholesterol-year-score was calculated as LDL-C max × [age at diagnosis/statin initiation] + LDL-C at inclusion × [age at inclusion - age at diagnosis/statin initiation]. The median follow-up period for MACE evaluation was 12.3 (interquartile range, 9.1-17.5) years, and 177 patients experienced MACEs during the observation period. Cholesterol-year-score was significantly associated with MACEs (hazard ratio, 1.35; 95% confidence interval, 1.07-1.53; P=0.0034, per 1,000 mg-year/dL), independent of other traditional risk factors including age and LDL-C, based on cross-sectional assessment. Cholesterol-year-score improved the discrimination ability of other traditional risk factors for ASCVD events (C-index, 0.901 vs. 0.889; P=0.00473).
CONCLUSIONS: Cumulative LDL-C exposure was strongly associated with MACEs in Japanese patients with FH, warranting early diagnosis and treatment initiation in these patients.

Entities:  

Keywords:  Cholesterol-year-score; Familial hypercholesterolemia; Low-density lipoprotein receptor; Proprotein convertase subtilisin/kexin type 9 (PCSK9)

Mesh:

Substances:

Year:  2021        PMID: 34011825     DOI: 10.1253/circj.CJ-21-0193

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia.

Authors:  Hayato Tada; Nobuko Kojima; Kan Yamagami; Akihiro Nomura; Atsushi Nohara; Soichiro Usui; Kenji Sakata; Noboru Fujino; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

2.  Clinical Nomogram to Predict Major Adverse Cardiac Events in Acute Myocardial Infarction Patients within 1 Year of Percutaneous Coronary Intervention.

Authors:  Defeng Pan; Shengjue Xiao; Yue Hu; Qinyuan Pan; Qi Wu; Xiaotong Wang; Qiaozhi Liu; Ailin Liu; Jie Liu; Hong Zhu; Yufei Zhou
Journal:  Cardiovasc Ther       Date:  2021-12-13       Impact factor: 3.023

Review 3.  Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism.

Authors:  Ana M González-Lleó; Rosa María Sánchez-Hernández; Mauro Boronat; Ana M Wägner
Journal:  Nutrients       Date:  2022-04-03       Impact factor: 5.717

4.  Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report.

Authors:  Anastasia V Blokhina; Alexandra I Ershova; Alexey N Meshkov; Anna V Kiseleva; Marina V Klimushina; Anastasia A Zharikova; Evgeniia A Sotnikova; Vasily E Ramensky; Oxana M Drapkina
Journal:  Front Cardiovasc Med       Date:  2022-08-25

Review 5.  Individualized Treatment for Patients With Familial Hypercholesterolemia.

Authors:  Hayato Tada; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Lipid Atheroscler       Date:  2022-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.